US36322Q1076 - Common Stock
GALECTO INC
NASDAQ:GLTO (5/2/2024, 8:45:17 AM)
0.69
+0.01 (+1.46%)
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Boston, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2020-10-29. The firm is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The firm is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.
GALECTO INC
75 State Street, Suite 100
Boston MASSACHUSETTS DK-2200
P: 14570705210
CEO: Hans T. Schambye
Employees: 45
Website: https://galecto.com/
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study...
GLTO stock results show that Galecto beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galecto (NASDAQ:GLTO) just reported results for the fourth quarter of 2023.Gale...
Galecto (GLTO) stock rallied 25% in post-market trading Thursday on positive Phase 2 data for the company's myelofibrosis drug. Read more here.
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis...
Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three...
Here you can normally see the latest stock twits on GLTO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: